{
  "risk_score_0_to_1": 0.72,
  "confidence_0_to_1": 0.85,
  "dominant_mechanisms": [
    {"mechanism": "mitochondrial_dysfunction", "score_0_to_1": 0.85},
    {"mechanism": "reactive_metabolite_formation", "score_0_to_1": 0.80},
    {"mechanism": "cholestasis_bsep_inhibition", "score_0_to_1": 0.45},
    {"mechanism": "immune_mediated_injury", "score_0_to_1": 0.70},
    {"mechanism": "oxidative_stress", "score_0_to_1": 0.75}
  ],
  "time_to_onset": "subacute_weeks_to_months",
  "dose_dependence": "mixed_idiosyncratic_and_dose_related",
  "reversibility": "reversible_if_early",
  "uncertainties": [
    "UGT2B7 polymorphisms and acyl glucuronide stability show variable individual impact",
    "Why diclofenac shows higher hepatotoxicity than other NSAIDs despite shared COX inhibition unclear",
    "HLA associations reported but not consistently replicated across populations",
    "Relative contribution of parent drug versus acyl glucuronide metabolite debated"
  ],
  "citations": [
    "Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol. 2003;192(3):307-322.",
    "Aithal GP, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806-815.",
    "Daly AK, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816-819."
  ]
}